

Francesco Frassoni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7784981/publications.pdf>

Version: 2024-02-01

228
papers

20,741
citations

19657

61
h-index

10445

139
g-index

231
all docs

231
docs citations

231
times ranked

16794
citing authors

#	ARTICLE	IF	CITATIONS
1	Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants. Science, 2002, 295, 2097-2100.	12.6	3,071
2	Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, The, 2008, 371, 1579-1586.	13.7	2,474
3	Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood, 2005, 106, 1755-1761.	1.4	1,318
4	Transplants of Umbilical-Cord Blood or Bone Marrow from Unrelated Donors in Adults with Acute Leukemia. New England Journal of Medicine, 2004, 351, 2276-2285.	27.0	1,058
5	Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet, The, 1998, 352, 1087-1092.	13.7	609
6	Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood, 2003, 102, 814-819.	1.4	515
7	Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Annals of Neurology, 2007, 61, 219-227.	5.3	450
8	Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica, 2005, 90, 516-25.	3.5	444
9	Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia, 2005, 19, 2304-2312.	7.2	417
10	Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell-depleted SCT. Blood, 2001, 98, 972-978.	1.4	342
11	A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood, 2008, 112, 3574-3581.	1.4	261
12	Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study. Lancet Oncology, The, 2008, 9, 831-839.	10.7	244
13	Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 17384-17389.	7.1	241
14	Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus?. Blood, 2012, 119, 399-410.	1.4	241
15	Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplantation, 2005, 36, 757-769.	2.4	232
16	Human Mesenchymal Stem Cells Promote Survival of T Cells in a Quiescent State. Stem Cells, 2007, 25, 1753-1760.	3.2	231
17	Donor CMV serologic status and outcome of CMV-seropositive recipients after unrelated donor stem cell transplantation: an EBMT megafile analysis. Blood, 2003, 102, 4255-4260.	1.4	217
18	Multiple infusions of mesenchymal stromal cells induce sustained remission in children with steroid-refractory, grade III-IV acute graft-versus-host disease. British Journal of Haematology, 2013, 163, 501-509.	2.5	213

#	ARTICLE	IF	CITATIONS
19	The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group. Multiple Sclerosis Journal, 2010, 16, 503-510.	3.0	212
20	Diagnostic and clinical relevance of the number of circulating CD34+ cells in myelofibrosis with myeloid metaplasia. Blood, 2001, 98, 3249-3255.	1.4	197
21	Blood Stream Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Reemergence of Gram-Negative Rods and Increasing Antibiotic Resistance. Biology of Blood and Marrow Transplantation, 2009, 15, 47-53.	2.0	189
22	Human Cytomegalovirus Infection Promotes Rapid Maturation of NK Cells Expressing Activating Killer Ig-like Receptor in Patients Transplanted with NKG2C ^{hi} Umbilical Cord Blood. Journal of Immunology, 2014, 192, 1471-1479.	0.8	176
23	Second Allogeneic Bone Marrow Transplantation in Acute Leukemia: Results of a Survey by the European Cooperative Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2001, 19, 3675-3684.	1.6	173
24	Treatment With Granulocyte Colony-Stimulating Factor After Allogeneic Bone Marrow Transplantation for Acute Leukemia Increases the Risk of Graft-Versus-Host Disease and Death: A Study From the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Journal of Clinical Oncology, 2004, 22, 416-423.	1.6	173
25	Quality of life in 244 recipients of allogeneic bone marrow transplantation. British Journal of Haematology, 2000, 110, 614-619.	2.5	164
26	Multipotent mesenchymal stromal cells from amniotic fluid: solid perspectives for clinical application. Haematologica, 2008, 93, 339-346.	3.5	159
27	Human mesenchymal stem cells inhibit antibody production induced in vitro by allostimulation. Nephrology Dialysis Transplantation, 2007, 23, 1196-1202.	0.7	142
28	Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood, 2002, 100, 3877-3886.	1.4	141
29	Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type. Bone Marrow Transplantation, 2010, 45, 458-463.	2.4	141
30	Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. British Journal of Haematology, 2001, 112, 219-227.	2.5	137
31	Transplantation of Peripheral Blood Stem Cells as Compared With Bone Marrow From HLA-Identical Siblings in Adult Patients With Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2002, 20, 4655-4664.	1.6	136
32	Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 1997, 20, 553-560.	2.4	134
33	Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases. British Journal of Haematology, 1988, 70, 317-320.	2.5	117
34	T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Experimental Hematology, 2005, 33, 819-827.	0.4	109
35	Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Lancet, The, 2000, 355, 1393-1398.	13.7	99
36	Selective effect of feline leukaemia virus on early erythroid precursors. Nature, 1982, 296, 156-158.	27.8	97

#	ARTICLE	IF	CITATIONS
37	Hematopoietic stem cell transplantation for hematological malignancies in Europe. <i>Leukemia</i> , 2003, 17, 941-959.	7.2	93
38	Achieving a Major Molecular Response at the Time of a Complete Cytogenetic Response (CCgR) Predicts a Better Duration of CCgR in Imatinib-Treated Chronic Myeloid Leukemia Patients. <i>Clinical Cancer Research</i> , 2006, 12, 3037-3042.	7.0	90
39	Factors predicting response and graft-versus-host disease after donor lymphocyte infusions: a study on 593 infusions. <i>Bone Marrow Transplantation</i> , 2003, 31, 687-693.	2.4	89
40	Transplant-related mortality and long-term graft function are significantly influenced by cell dose in patients undergoing allogeneic marrow transplantation. <i>Blood</i> , 2002, 100, 3930-3934.	1.4	88
41	MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation. <i>Oncotarget</i> , 2016, 7, 6676-6692.	1.8	86
42	Recurrence of Ph ⁺ -Positive Leukemia in Donor Cells after Marrow Transplantation for Chronic Granulocytic Leukemia. <i>New England Journal of Medicine</i> , 1984, 310, 903-906.	27.0	83
43	In vivo B-cell depletion with rituximab for alternative donor hemopoietic SCT. <i>Bone Marrow Transplantation</i> , 2012, 47, 101-106.	2.4	83
44	Unbalanced X ^h -chromosome inactivation in haemopoietic cells from normal women. <i>British Journal of Haematology</i> , 1998, 102, 996-1003.	2.5	81
45	Endothelial colony-forming cells from patients with chronic myeloproliferative disorders lack the disease-specific molecular clonality marker. <i>Blood</i> , 2009, 114, 3127-3130.	1.4	79
46	The Ultrastructural Localization of Factor VIII-Antigen in Human Platelets, Megakaryocytes and Endothelial Cells Utilizing a Ferritin-labelled Antibody. <i>British Journal of Haematology</i> , 1978, 39, 209-213.	2.5	78
47	Cord blood transplantation provides better reconstitution of hematopoietic reservoir compared with bone marrow transplantation. <i>Blood</i> , 2003, 102, 1138-1141.	1.4	76
48	Intra ^u -bone marrow injection of bone marrow and cord blood cells: an alternative way of transplantation associated with a higher seeding efficiency. <i>Experimental Hematology</i> , 2004, 32, 782-787.	0.4	76
49	Diabetes Impairs the Vascular Recruitment of Normal Stem Cells by Oxidant Damage, Reversed by Increases in pAMPK, Heme Oxygenase-1, and Adiponectin. <i>Stem Cells</i> , 2009, 27, 399-407.	3.2	75
50	Identical Outcome After Autologous or Allogeneic Genoidentical Hematopoietic Stem-Cell Transplantation in First Remission of Acute Myelocytic Leukemia Carrying Inversion 16 or t(8;21): A Retrospective Study From the European Cooperative Group for Blood and Marrow Transplantation. <i>Journal of Clinical Oncology</i> , 2008, 26, 3183-3188.	1.6	73
51	Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor- κ B and p53 modulation. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 2692-2702.	4.1	73
52	Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia. <i>Blood</i> , 2007, 109, 5063-5064.	1.4	72
53	p38 MAPK and JNK Antagonistically Control Senescence and Cytoplasmic p16INK4A Expression in Doxorubicin-Treated Endothelial Progenitor Cells. <i>PLoS ONE</i> , 2010, 5, e15583.	2.5	70
54	IN VIVO MOBILIZATION OF KARYOTYPICALLY NORMAL PERIPHERAL BLOOD PROGENITOR CELLS IN HIGH-RISK MDS, SECONDARY OR THERAPY-RELATED ACUTE MYELOGENOUS LEUKAEMIA. <i>British Journal of Haematology</i> , 1996, 95, 127-130.	2.5	68

#	ARTICLE	IF	CITATIONS
55	Mobilization and transplantation of Philadelphia-negative peripheral-blood progenitor cells early in chronic myelogenous leukemia.. Journal of Clinical Oncology, 1997, 15, 1575-1582.	1.6	68
56	Unrelated Cord Blood Transplantation. Transplantation, 2013, 95, 1284-1291.	1.0	66
57	The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia. Blood, 1998, 91, 1959-1965.	1.4	65
58	Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplantation, 2002, 29, 639-646.	2.4	65
59	Relevance of Bone Marrow Cell Dose on Allogeneic Transplantation Outcomes for Patients With Acute Myeloid Leukemia in First Complete Remission: Results of a European Survey. Journal of Clinical Oncology, 2002, 20, 4324-4330.	1.6	65
60	No impact of high-dose cytarabine on the outcome of patients transplanted for acute myeloblastic leukaemia in first remission. British Journal of Haematology, 2000, 110, 308-314.	2.5	64
61	ABO COMPATIBILITY AND ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. Transplantation, 1988, 45, 1091-1093.	1.0	63
62	Stem cells in inflammatory demyelinating disorders: a dual role for immunosuppression and neuroprotection. Expert Opinion on Biological Therapy, 2006, 6, 17-22.	3.1	63
63	Exosomes from human mesenchymal stem cells conduct aerobic metabolism in term and preterm newborn infants. FASEB Journal, 2016, 30, 1416-1424.	0.5	63
64	Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. British Journal of Haematology, 2000, 111, 1130-1137.	2.5	63
65	Helical tomotherapy targeting total bone marrow after total body irradiation for patients with relapsed acute leukemia undergoing an allogeneic stem cell transplant. Radiotherapy and Oncology, 2011, 98, 382-386.	0.6	62
66	Rituximab Treatment for Epstein-Barr Virus DNAemia after Alternative-Donor Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 901-907.	2.0	59
67	Mesenchymal Stem Cells Infusion Prevents Acute Cellular Rejection in Rat Kidney Transplantation. Transplantation Proceedings, 2010, 42, 1331-1335.	0.6	58
68	Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2007, 39, 461-469.	2.4	55
69	Reduced intensity thiotepa-cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age. British Journal of Haematology, 2000, 109, 716-721.	2.5	54
70	Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: influence of dose and stem cell source shows better outcome with rich marrow. Blood, 2003, 102, 3043-3051.	1.4	52
71	Mesenchymal Stem Cells Protective Effect in Adriamycin Model of Nephropathy. Cell Transplantation, 2008, 17, 1157-1167.	2.5	52
72	Human Mesenchymal Stem Cells and Cyclosporin A Exert a Synergistic Suppressive Effect on In Vitro Activation of Alloantigen-Specific Cytotoxic Lymphocytes. Biology of Blood and Marrow Transplantation, 2005, 11, 1031-1032.	2.0	51

#	ARTICLE	IF	CITATIONS
73	Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1326-1338.	6.4	51
74	Prophylactic antithymocyte globulin reduces the risk of chronic graft-versus-host disease in alternative-donor bone marrow transplants. <i>Biology of Blood and Marrow Transplantation</i> , 2002, 8, 656-661.	2.0	50
75	HLA-identical sibling allogeneic peripheral blood stem cell transplantation with reduced intensity conditioning compared to autologous peripheral blood stem cell transplantation for elderly patients with de novo acute myeloid leukemia. <i>Leukemia</i> , 2007, 21, 129-135.	7.2	50
76	Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow. <i>Bone Marrow Transplantation</i> , 2003, 31, 23-29.	2.4	49
77	Clinical scale ex vivo expansion of cord blood-derived outgrowth endothelial progenitor cells is associated with high incidence of karyotype aberrations. <i>Experimental Hematology</i> , 2008, 36, 340-349.	0.4	49
78	High dose bolus methylprednisolone for the treatment of acute graft versus host disease. <i>Blut</i> , 1983, 46, 125-132.	1.2	48
79	Which Is the Most Suitable and Effective Route of Administration for Mesenchymal Stem Cell-Based Immunomodulation Therapy in Experimental Kidney Transplantation: Endovenous or Arterial?. <i>Transplantation Proceedings</i> , 2010, 42, 1336-1340.	0.6	48
80	The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 2000, 108, 99-104.	2.5	46
81	Massive chemotherapy with non-frozen autologous bone marrow transplantation in 13 cases of refractory Hodgkin's disease. <i>European Journal of Cancer & Clinical Oncology</i> , 1985, 21, 607-613.	0.7	45
82	Pre-emptive therapy of acute graft-versus-host disease: a pilot study with antithymocyte globulin (ATG). <i>Bone Marrow Transplantation</i> , 2001, 28, 1093-1096.	2.4	45
83	The retroviral transduction of HOXC4 into human CD34+ cells induces an in vitro expansion of clonogenic and early progenitors. <i>Experimental Hematology</i> , 2000, 28, 569-574.	0.4	44
84	Dose-effect relationship for cataract induction after single-dose total body irradiation and bone marrow transplantation for acute leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2002, 52, 1367-1374.	0.8	43
85	Donor multipotent mesenchymal stromal cells may engraft in pediatric patients given either cord blood or bone marrow transplantation. <i>Experimental Hematology</i> , 2006, 34, 934-942.	0.4	42
86	Induction and Survival of Binucleated Purkinje Neurons by Selective Damage and Aging. <i>Journal of Neuroscience</i> , 2007, 27, 9885-9892.	3.6	42
87	Late Development of FcÎ³R ³ neg Adaptive Natural Killer Cells Upon Human Cytomegalovirus Reactivation in Umbilical Cord Blood Transplantation Recipients. <i>Frontiers in Immunology</i> , 2018, 9, 1050.	4.8	42
88	Discrete Changes in Glucose Metabolism Define Aging. <i>Scientific Reports</i> , 2019, 9, 10347.	3.3	42
89	Total body irradiation in acute myeloid leukemia and chronic myelogenous leukemia: influence of dose and dose-rate on leukemia relapse. <i>International Journal of Radiation Oncology Biology Physics</i> , 1989, 17, 547-552.	0.8	41
90	Haemopoietic colony formation (BFU-E, GM-CFC) during the development of pure red cell hypoplasia induced in the cat by feline leukaemia virus. <i>Leukemia Research</i> , 1983, 7, 103-116.	0.8	40

#	ARTICLE	IF	CITATIONS
91	Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Bone Marrow Transplantation, 1999, 24, 389-396.	2.4	39
92	Hematopoietic stem cell transplantation for de novo acute megakaryocytic leukemia in first complete remission: a retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2005, 105, 405-409.	1.4	39
93	Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1997, 19, 1011-1017.	2.4	38
94	Mesenchymal stromal cells, from indifferent spectators to principal actors. Are we going to witness a revolution in the scenario of allograft and immune-mediated disorders?. Haematologica, 2007, 92, 872-877.	3.5	37
95	Twelve Years Experience with High-Dose Therapy and Autologous Stem Cell Transplantation for High-Risk Hodgkin's Disease Patients in First Remission After MOPP/ABVD Chemotherapy. Leukemia and Lymphoma, 1996, 21, 63-70.	1.3	36
96	Molecular Follow-Up of Disease Progression and Interferon Therapy in Chronic Myelocytic Leukemia. Blood, 1997, 90, 4918-4923.	1.4	36
97	Association of Human Development Index with rates and outcomes of hematopoietic stem cell transplantation for patients with acute leukemia. Blood, 2010, 116, 122-128.	1.4	36
98	Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia. British Journal of Haematology, 1988, 69, 471-475.	2.5	36
99	Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience. Bone Marrow Transplantation, 1997, 20, 1057-1062.	2.4	34
100	Fractionated total body irradiation in marrow transplantation for leukaemia. British Journal of Haematology, 1983, 55, 547-554.	2.5	33
101	Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells. British Journal of Haematology, 2000, 110, 887-893.	2.5	32
102	A novel Bim-BH3-derived Bcl-XL inhibitor: Biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity. Cell Cycle, 2008, 7, 3211-3224.	2.6	32
103	The dismal outcome in patients with acute leukaemia who relapse after an autograft is improved if a second autograft or a matched allograft is performed. Bone Marrow Transplantation, 2000, 25, 1053-1058.	2.4	31
104	Increased risk of leukemia relapse with high dose cyclosporine after allogeneic marrow transplantation for acute leukemia: 10 year follow-up of a randomized study. Blood, 2001, 98, 3174-3174.	1.4	31
105	CMV Infection after Transplant from Cord Blood Compared to Other Alternative Donors: The Importance of Donor-Negative CMV Serostatus. Biology of Blood and Marrow Transplantation, 2012, 18, 92-99.	2.0	31
106	High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis. PLoS ONE, 2010, 5, e15277.	2.5	30
107	Improving the outcome of umbilical cord blood transplantation through ex vivo expansion or graft manipulation. Cytotherapy, 2015, 17, 730-738.	0.7	30
108	High-dose chemotherapy and non-frozen autologous bone marrow transplantation in relapsed advanced lymphomas or those resistant to conventional chemotherapy. Cancer, 1984, 54, 2836-2839.	4.1	29

#	ARTICLE	IF	CITATIONS
109	Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: an update of the Genoa experience with 159 patients. <i>Annals of Hematology</i> , 1992, 64, 128-131.	1.8	29
110	Freshly dissociated fetal neural stem/progenitor cells do not turn into blood. <i>Molecular and Cellular Neurosciences</i> , 2003, 22, 179-187.	2.2	29
111	The intra-bone marrow injection of cord blood cells extends the possibility of transplantation to the majority of patients with malignant hematopoietic diseases. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 237-244.	1.7	29
112	The effect of total body irradiation dose and chronic graft-versus-host disease on leukaemic relapse after allogeneic bone marrow transplantation. <i>British Journal of Haematology</i> , 1989, 73, 211-216.	2.5	28
113	Restoration of normal polyclonal haemopoiesis in patients with chronic myeloid leukaemia autografted with Ph ⁺ negative peripheral stem cells. <i>British Journal of Haematology</i> , 1994, 87, 867-870.	2.5	28
114	Factors influencing outcome and incidence of long-term complications in children who underwent autologous stem cell transplantation for acute myeloid leukemia in first complete remission. <i>Blood</i> , 2003, 101, 1611-1619.	1.4	28
115	Coexistence of normal and clonal haemopoiesis in aplastic anaemia patients treated with immunosuppressive therapy. <i>British Journal of Haematology</i> , 1999, 107, 505-511.	2.5	27
116	Chromosome studies in patients with Philadelphia chromosome-positive chronic myeloid leukemia submitted to bone marrow transplantation—Results of a European cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987, 26, 5-13.	1.0	26
117	A revised day +7 predictive score for transplant-related mortality: serum cholinesterase, total protein, blood urea nitrogen, γ glutamyl transferase, donor type and cell dose. <i>Bone Marrow Transplantation</i> , 2003, 32, 205-211.	2.4	26
118	Mesenchymal stromal cells improve renal injury in anti-Thy 1 nephritis by modulating inflammatory cytokines and scatter factors. <i>Clinical Science</i> , 2011, 120, 25-36.	4.3	26
119	Mesenchymal stem cells from preterm to term newborns undergo a significant switch from anaerobic glycolysis to the oxidative phosphorylation. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 889-903.	5.4	26
120	Philadelphia-chromosome-negative peripheral blood stem cells can be mobilized in the early phase of recovery after a myelosuppressive chemotherapy in Philadelphia-chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 1995, 89, 535-538.	2.5	25
121	Strong antileukemic effect of chronic graft-versus-host disease in allogeneic marrow transplant recipients having acute leukemia treated with methotrexate and cyclosporine. <i>Transplantation Proceedings</i> , 1997, 29, 733-734.	0.6	25
122	Total body irradiation correlates with chronic graft versus host disease and affects prognosis of patients with acute lymphoblastic leukemia receiving an HLA identical allogeneic bone marrow transplant. <i>International Journal of Radiation Oncology Biology Physics</i> , 1999, 43, 497-503.	0.8	25
123	Nonhuman primate allogeneic hematopoietic stem cell transplantation by intraosseous vs intravenous injection: Engraftment, donor cell distribution, and mechanistic basis. <i>Experimental Hematology</i> , 2008, 36, 1556-1566.	0.4	25
124	The impact of center experience on results of reduced intensity: allogeneic hematopoietic SCT for AML. An analysis from the Acute Leukemia Working Party of the EBMT. <i>Bone Marrow Transplantation</i> , 2013, 48, 238-242.	2.4	25
125	Phenotypic and functional analysis of the HLA-class II-specific inhibitory receptors of natural killer cells isolated from peripheral blood of patients undergoing bone marrow transplantation from matched unrelated donors. <i>The Hematology Journal</i> , 2000, 1, 136-144.	1.4	25
126	Evidence of cytogenetic and molecular remission by allogeneic cells after immunosuppressive therapy alone. <i>British Journal of Haematology</i> , 1998, 103, 565-567.	2.5	24

#	ARTICLE	IF	CITATIONS
127	Prediction of response to imatinib by prospective quantitation of BCR-ABL transcript in late chronic phase chronic myeloid leukemia patients. <i>Annals of Oncology</i> , 2006, 17, 495-502.	1.2	24
128	Adult Advanced Chronic Lymphocytic Leukemia: Computational Analysis of Whole-Body CT Documents a Bone Structure Alteration. <i>Radiology</i> , 2014, 271, 805-813.	7.3	24
129	Preterm Cord Blood Contains a Higher Proportion of Immature Hematopoietic Progenitors Compared to Term Samples. <i>PLoS ONE</i> , 2015, 10, e0138680.	2.5	24
130	Generation of CFU-C suppressor T cells in vitro: V. A. MULTISTEP PROCESS. <i>British Journal of Haematology</i> , 1982, 52, 421-427.	2.5	23
131	Donor-recipient incompatibility at CD31-codon 563 is a major risk factor for acute graft-versus-host disease after allogeneic bone marrow transplantation from a human leucocyte antigen-matched donor. <i>British Journal of Haematology</i> , 2001, 114, 951-953.	2.5	23
132	Hematopoietic stem cell transplantation for de novo erythroleukemia: a study of the European Group for Blood and Marrow Transplantation (EBMT). <i>Blood</i> , 2002, 100, 3135-3140.	1.4	23
133	Mesenchymal Stromal Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2007, 13, 53-57.	2.0	23
134	Mesenchymal stromal cells reset the scatter factor system and cytokine network in experimental kidney transplantation. <i>BMC Immunology</i> , 2014, 15, 44.	2.2	23
135	Allogeneic cell transplant expands bone marrow distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. <i>Blood</i> , 2015, 125, 4095-4102.	1.4	23
136	Issues in the manufacture and transplantation of genetically modified hematopoietic stem cells. <i>Current Opinion in Hematology</i> , 2000, 7, 364-377.	2.5	22
137	Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. <i>Bone Marrow Transplantation</i> , 2007, 40, 349-354.	2.4	22
138	Bone marrow transplantation for chronic granulocytic leukemia. <i>Cancer</i> , 1986, 58, 2307-2311.	4.1	21
139	Karyotype evolution of Ph positive chronic myelogenous leukemia patients relapsed in advanced phases of the disease after allogeneic bone marrow transplantation. <i>Cancer Genetics and Cytogenetics</i> , 1991, 57, 69-78.	1.0	21
140	Contact with the bone marrow microenvironment readdresses the fate of transplanted hematopoietic stem cells. <i>Experimental Hematology</i> , 2010, 38, 968-977.	0.4	21
141	Bone marrow or peripheral blood as a source of stem cells for allogeneic transplants. <i>Current Opinion in Hematology</i> , 2000, 7, 343-347.	2.5	20
142	Risk assessment in adult acute lymphoblastic leukaemia before early haemopoietic stem cell transplantation with a geno-identical donor: an easy clinical prognostic score to identify patients who benefit most from allogeneic haemopoietic stem cell transplantation. <i>Leukemia</i> , 2003, 17, 1596-1599.	7.2	20
143	Is there a place for autologous bone marrow transplantation in chronic myeloid leukemia?. <i>Stem Cells</i> , 1993, 11, 1-3.	3.2	19
144	Randomised studies in acute myeloid leukaemia: the double truth. <i>Bone Marrow Transplantation</i> , 2000, 25, 471-472.	2.4	19

#	ARTICLE	IF	CITATIONS
145	Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms. <i>Haematologica</i> , 2009, 94, 967-974.	3.5	19
146	Effective mobilization of Philadelphia-chromosome-negative cells in chronic myelogenous leukaemia patients using a less intensive regimen. <i>British Journal of Haematology</i> , 1998, 100, 445-448.	2.5	18
147	Chromosome studies in patients with acute nonlymphocytic or acute lymphocytic leukemia submitted to bone marrow transplantation—Results of a European cooperative study. <i>Cancer Genetics and Cytogenetics</i> , 1987, 26, 51-58.	1.0	17
148	Selective overshoot of Philadelphia-negative blood hemopoietic cells after intensive idarubicin-containing regimen and their repopulating capacity after reinfusion. <i>Stem Cells</i> , 1993, 11, 67-72.	3.2	17
149	Idarubicin, Intermediate-Dose Cytarabine, Etoposide, and Granulocyte-Colony-Stimulating Factor Are Able to Recruit CD34+/HLA-DR-Cells During Early Hematopoietic Recovery in Accelerated and Chronic Phases of Chronic Myeloid Leukemia. <i>Stem Cells and Development</i> , 1994, 3, 199-202.	1.0	17
150	Splenic irradiation before bone marrow transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1996, 95, 494-500.	2.5	17
151	Competition between recipient and donor cells after bone marrow transplantation for chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 1988, 69, 471-475.	2.5	17
152	Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2013, 37, 520-530.	0.8	17
153	High Dose BCNU Followed by Autologous Bone Marrow Infusion in Glioblastoma Multiforme. <i>Tumori</i> , 1981, 67, 473-475.	1.1	16
154	GRAFT-VERSUS-LEUKAEMIA EFFECT FOLLOWING ALLOGENEIC BONE MARROW TRANSPLANTATION. <i>British Journal of Haematology</i> , 1985, 61, 749-751.	2.5	15
155	Competitive survival/proliferation of normal and Ph1-positive haemopoietic cells. <i>British Journal of Haematology</i> , 1986, 63, 135-141.	2.5	15
156	In haematopoietic SCT for acute leukemia TBI impacts on relapse but not survival: results of a multicentre observational study. <i>Bone Marrow Transplantation</i> , 2013, 48, 908-914.	2.4	15
157	EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 483-496.	4.4	15
158	Cytogenetic follow-up after bone marrow transplantation for Philadelphia-positive chronic myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1989, 42, 253-261.	1.0	14
159	Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up. <i>Bone Marrow Transplantation</i> , 2007, 40, 1091-1093.	2.4	14
160	Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission. <i>Haematologica</i> , 2008, 93, 834-841.	3.5	14
161	Deferasirox-Dependent Iron Chelation Enhances Mitochondrial Dysfunction and Restores p53 Signaling by Stabilization of p53 Family Members in Leukemic Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 7674.	4.1	14
162	Intravenous Monoclonal Antibody (BT 5/9) for the Treatment of Acute Graft-versus-Host Disease. <i>Acta Haematologica</i> , 1985, 73, 185-186.	1.4	13

#	ARTICLE	IF	CITATIONS
163	The relative spatial distribution of erythroid progenitor cells (BFUe and CFUe) in the normal mouse femur. <i>Cell Proliferation</i> , 1982, 15, 447-455.	5.3	12
164	Differential effects of the type of iron chelator on the absolute number of hematopoietic peripheral progenitors in patients with α -thalassemia major. <i>Haematologica</i> , 2013, 98, 555-559.	3.5	12
165	Clonal haematopoiesis is not prevalent in survivors of childhood cancer. <i>British Journal of Haematology</i> , 2018, 181, 537-539.	2.5	12
166	Acyclovir for the Treatment of Severe Aplastic Anemia. <i>New England Journal of Medicine</i> , 1984, 310, 1606-1607.	27.0	11
167	Variant Philadelphia translocations in CML: Correlation with fragile sites. <i>Cancer Genetics and Cytogenetics</i> , 1988, 31, 105-112.	1.0	11
168	Normal primitive haemopoietic progenitors are more frequent than their leukaemic counterpart in newly diagnosed patients with chronic myeloid leukaemia but rapidly decline with time. <i>British Journal of Haematology</i> , 1999, 104, 538-545.	2.5	11
169	Progenitor cells trapped in marrow filters can reduce GvHD and transplant mortality. <i>Bone Marrow Transplantation</i> , 2006, 38, 111-117.	2.4	11
170	Acute myelogenous leukemia with translocation t(8;21): A cytogenetic study of seven cases. <i>Cancer Genetics and Cytogenetics</i> , 1986, 20, 363-368.	1.0	10
171	Spontaneous exodus of high numbers of normal early progenitor cells (Ph ⁻ negative LTC ⁻ IC) in the peripheral blood of patients with chronic myeloid leukaemia at the beginning of the disease. <i>British Journal of Haematology</i> , 1997, 97, 94-98.	2.5	10
172	Allogeneic hemopoietic stem cell transplants for patients with relapsed acute leukemia: long-term outcome. <i>Bone Marrow Transplantation</i> , 2007, 39, 341-346.	2.4	10
173	Radiomics and Artificial Intelligence for Outcome Prediction in Multiple Myeloma Patients Undergoing Autologous Transplantation: A Feasibility Study with CT Data. <i>Diagnostics</i> , 2021, 11, 1759.	2.6	10
174	Efficient long-term maintenance of chronic myeloid leukemic cobblestone area forming cells on a murine stromal cell line. <i>Leukemia</i> , 1997, 11, 126-133.	7.2	9
175	Iron overload alters the energy metabolism in patients with myelodysplastic syndromes: results from the multicenter FISM BIOFER study. <i>Scientific Reports</i> , 2020, 10, 9156.	3.3	9
176	Variable but consistent pattern of Meningioma 1 gene (<i>MN1</i>) expression in different genetic subsets of acute myelogenous leukaemia and its potential use as a marker for minimal residual disease detection. <i>Oncotarget</i> , 2016, 7, 74082-74096.	1.8	9
177	Generation of CFU-C Suppressor T Cells. <i>Acta Haematologica</i> , 1983, 70, 163-169.	1.4	8
178	Idarubicin alone or in combination with citarabine and etoposide (3 + 3 + 5 protocol) in acute non-lymphoblastic leukaemia. <i>Leukemia Research</i> , 1985, 9, 631.	0.8	8
179	Serum cholinesterase is an early and sensitive marker of graft-versus host-disease (GVHD) and transplant-related mortality (TRM). <i>Bone Marrow Transplantation</i> , 2001, 28, 1041-1045.	2.4	8
180	Modified in vitro conditions for cord blood ⁻ derived long-term culture-initiating cells. <i>Experimental Hematology</i> , 2001, 29, 309-314.	0.4	8

#	ARTICLE	IF	CITATIONS
181	Reassessing autotransplantation for acute myeloid leukaemia in first remission – a matched pair analysis of autologous marrow vs peripheral blood stem cells. Bone Marrow Transplantation, 2004, 33, 1209-1214.	2.4	8
182	Abnormalities of Na/K ATPase in Migraine With Aura. Cephalalgia, 2007, 27, 128-132.	3.9	8
183	Intrabone Transplant of Cord Blood Stem Cells Establishes a Local Engraftment Store: A Functional PET/FDG Study. Journal of Biomedicine and Biotechnology, 2012, 2012, 1-8.	3.0	8
184	Detection of BCR-ABL T315I mutation by peptide nucleic acid directed PCR clamping and by peptide nucleic acid FISH. Biomarker Research, 2015, 3, 15.	6.8	8
185	The Wilms’s tumor (WT1) gene expression correlates with the International Prognostic Scoring System (IPSS) score in patients with myelofibrosis and it is a marker of response to therapy. Cancer Medicine, 2016, 5, 1650-1653.	2.8	8
186	Stem cells for multiple sclerosis: promises and reality. Regenerative Medicine, 2007, 2, 7-9.	1.7	7
187	A novel assay to detect calreticulin mutations in myeloproliferative neoplasms. Oncotarget, 2017, 8, 6399-6405.	1.8	7
188	Bone Marrow Transplantation (BMT) for Acute Nonlymphoid Leukemia (ANLL) in First Remission. Acta Haematologica, 1985, 74, 23-26.	1.4	6
189	Stem-cell mobilization for autografting in chronic myeloid leukemia. Blood Reviews, 1997, 11, 154-159.	5.7	6
190	Anti-T-cell globulin: an essential ingredient for haematopoietic cell transplantation?. Lancet Oncology, The, 2009, 10, 839.	10.7	6
191	Impact of length of cryopreservation and origin of cord blood units on hematologic recovery following cord blood transplantation. Bone Marrow Transplantation, 2015, 50, 818-821.	2.4	6
192	Splenic irradiation before hematopoietic stem cell transplantation for chronic myeloid leukemia: long-term follow-up of a prospective randomized study. Annals of Hematology, 2016, 95, 967-972.	1.8	6
193	In vitro tests in severe aplastic anaemia (SAA): a prospective study in 46 patients treated with immunosuppression. British Journal of Haematology, 1985, 59, 611-616.	2.5	5
194	Molecular analysis of Philadelphia-negative myeloproliferative syndromes with i(17q). Cancer Genetics and Cytogenetics, 1989, 43, 195-201.	1.0	5
195	Late complications of allogeneic bone marrow transplantation. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 261-263.	1.1	5
196	Autografting with Ph-negative progenitors in patients at diagnosis of chronic myeloid leukemia induces a prolonged prevalence of Ph-negative hemopoiesis. Experimental Hematology, 2000, 28, 210-215.	0.4	5
197	Identification of Biochemical and Molecular Markers of Early Aging in Childhood Cancer Survivors. Cancers, 2021, 13, 5214.	3.7	5
198	Mepartricin: A New Antifungal Agent for the Treatment of Disseminated Candida Infections in the Immunocompromised Host. Acta Haematologica, 1983, 69, 409-413.	1.4	4

#	ARTICLE	IF	CITATIONS
199	Total body irradiation before allogeneic and autologous bone marrow transplantation: A ten year Genoa experience. <i>Radiotherapy and Oncology</i> , 1990, 18, 135-138.	0.6	4
200	Splenic Irradiation before Bone Marrow Transplantation for Chronic Myeloid Leukemia: Update of a Prospective Randomized Study. <i>Leukemia and Lymphoma</i> , 1993, 11, 227-231.	1.3	4
201	Is minimal residual disease in the peripheral-blood stem-cell transplantation of chronic myelogenous leukemia important?. <i>Journal of Clinical Oncology</i> , 1997, 15, 3166-3167.	1.6	4
202	Association of ex-vivo expanded human mesenchymal stem cells and rhBMP-7 is highly effective in treating critical femoral defect in rats. <i>Journal of Orthopaedics and Traumatology</i> , 2007, 8, 49-54.	2.3	4
203	Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms. <i>BMC Cancer</i> , 2013, 13, 348.	2.6	4
204	Transplantation Induces Profound Changes in the Transcriptional Asset of Hematopoietic Stem Cells: Identification of Specific Signatures Using Machine Learning Techniques. <i>Journal of Clinical Medicine</i> , 2020, 9, 1670.	2.4	4
205	Tobramycin versus Gentamicin, in Combination with Cephalotin and Carbenecillin, in Patients Undergoing Bone Marrow Transplantation. <i>Tumori</i> , 1981, 67, 525-532.	1.1	3
206	GM-CFC growth in chronic granulocytic leukaemia is not affected by a soluble inhibitor released by aplastic anaemia T-cells or mitogen-primed normal T-lymphocytes. <i>British Journal of Haematology</i> , 1982, 50, 647-653.	2.5	3
207	Human serum-dependent survival of GM-CFCs in vitro from patients with chronic granulocytic leukemia. <i>Leukemia Research</i> , 1987, 11, 3-6.	0.8	3
208	Normal and leukaemic haematopoiesis in bone marrow and peripheral blood of patients with chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 1999, 12, 199-208.	1.7	3
209	Cyclosporin A (CyA) does not enhance CFUâ€ growth in patients with severe aplastic anaemia. <i>Scandinavian Journal of Haematology</i> , 1985, 34, 133-136.	0.0	3
210	CIRCULATING IMMUNE COMPLEXES IN ALLOGENEIC MARROW GRAFT RECIPIENTS. <i>Transplantation</i> , 1984, 38, 428-429.	1.0	2
211	T-Derived Colony-Inhibiting Activity: Partial Characterization and Mechanism of Action. <i>Acta Haematologica</i> , 1985, 74, 195-199.	1.4	2
212	The Use of Glycopeptides as Empiric Antibiotic Therapy in Febrile Neutropenic Patients: A Comparison Between Teicoplanin (TEI) and Vancomycin (VAN). <i>Leukemia and Lymphoma</i> , 1992, 7, 110-111.	1.3	2
213	Mobilization/transplantation of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia. <i>Annals of Oncology</i> , 1996, 7, 19-22.	1.2	2
214	The laws covering in vitro fertilization and embryo research in Italy. <i>Bone Marrow Transplantation</i> , 2006, 38, 5-6.	2.4	2
215	SEX DIFFERENCES IN HUMAN LYMPHOCYTE Na,K-ATPase AS STUDIED BY LABELED OUIABAIN BINDING. <i>International Journal of Neuroscience</i> , 2007, 117, 275-285.	1.6	2
216	Mesenchymal stem cells for acute graft-versus-host disease â€ Authors' reply. <i>Lancet</i> , The, 2008, 372, 716.	13.7	2

#	ARTICLE	IF	CITATIONS
217	Autografting With Philadelphia Chromosome-“Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia. Blood, 1999, 93, 1534-1539.	1.4	2
218	Interferon- γ protects Philadelphia-negative progenitors from exhaustion in chronic myeloid leukemia patients with cytogenetic response. The Hematology Journal, 2001, 2, 26-32.	1.4	2
219	Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation. Medical Oncology and Tumor Pharmacotherapy, 1991, 8, 189-201.	1.1	2
220	Relapse after allogeneic BMT for chronic myeloid leukemia (CML) may be sustained by a small number of leukemic “stem cells”: a hypothesis. Bone Marrow Transplantation, 1999, 24, 689-691.	2.4	1
221	Biologic and clinical aspects of autologous stem cell transplantation with mobilized peripheral blood cells in chronic myelogenous leukemia. Current Oncology Reports, 2000, 2, 144-151.	4.0	1
222	Intra-bone route of administration offers new perspectives for safer transplantation of hematopoietic stem cells. Cytotherapy, 2010, 12, 5-6.	0.7	1
223	The Assessment of the Hematopoietic Reservoir After Immunosuppressive Therapy or Bone Marrow Transplantation in Severe Aplastic Anemia. Blood, 1998, 91, 1959-1965.	1.4	1
224	Clinical Problems Associated with T Cell Depletion for Bone Marrow Transplantation. Annals of the New York Academy of Sciences, 1987, 511, 459-463.	3.8	0
225	Reply to Drs Caocci and Pisu. Bone Marrow Transplantation, 2006, 38, 830-831.	2.4	0
226	New possibilities to exploit the potentiality of cord blood cells in the context of transplantation. Immunology Letters, 2013, 155, 24-26.	2.5	0
227	Hematopoietic stem cell transplantation. Current Opinion in Hematology, 2000, 7, 331-332.	2.5	0
228	Hematopoietic stem cell transplantation. Current Opinion in Hematology, 2001, 8, 327-329.	2.5	0